Reviewing the reality: Why we need to change

European Heart Journal, Supplement

Volumn 7, Issue E, 2005, Pages

  Lin, Peter J ^a  

^a CANADIAN HEART RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTITHROMBOCYTIC AGENT; BARBITURIC ACID; CARBAMAZEPINE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; RIFAMPICIN; SULFINPYRAZONE; THROMBIN INHIBITOR; TRIMETHOPRIM; WARFARIN; XIMELAGATRAN;

ANEMIA; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CIGARETTE SMOKING; COMORBIDITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GENETIC RESISTANCE; GERIATRIC PATIENT; HEMATOMA; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; PATIENT MONITORING; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; RISK; STROKE; THROMBOEMBOLISM;

EID: 20844437551     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui031     Document Type: Review

References (44)

1. Völler H. In defence of current treatment options: where are we now? Eur Heart J Suppl 2005;7:E4-E9.
2. Gustafsson D, Bylund R, Antonsson T et al. A new oral anticoagulant: the 50-year challenge. Nat Rev Drug Discov 2004;3:649-659.
3. Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. J Biol Chem 1941;138:21-33.
4. Allen EV, Baker NW, Waugh JM. A preparation from spoiled sweet clover [3,3′-methylene-bis-(4-hydroxy-coumarin)] which prolongs coagulation and prothrombin time of the blood: A clinical study. JAMA 1942;120:1009-1015.
5. Link KP. The discovery of dicumarol and its sequels. Circulation 1959;19:97-107.
6. Schenone M, Furie BC, Furie B. The blood coagulation cascade. Curr Opin Hematol 2004;11:272-277.
7. Davie EW. A brief historical review of the waterfall/cascade of blood coagulation. J Biol Chem 2003;278:50819-50832.
8. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995;74:1-6.
9. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991;30:10363-10370.
10. Abusaada K, Sharma SB, Jaladi R et al. Epidemiology and management of new-onset atrial fibrillation. Am J Manag Care 2004;10: S50-S57.
11. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12.
12. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:645-945.
13. Hirsh J, Anand SS, Halperin JL et al. AHA Scientific Statement: Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Arterioscler Thromb Vasc Biol 2001;21:E9.
14. Wawrzynska L, Tomkowski WZ, Przedlacki J et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003;33:64-67.
15. Prydz H. Vitamin K-dependent clotting factors. Semin Thromb Hemost 1977;4:1-14.
16. Hirsh J, Fuster V, Ansell J et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003;41:1633-1652.
17. Dale J, Myhre E, Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J 1980;99:746-752.
18. Ansell J, Hirsh J, Dalen J et al. Managing oral anticoagulant therapy. Chest 2001;119:22S-38S.
19. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-152.
20. Suttie JW, Mummah-Schendel LL, Shah DV et al. Vitamin K deficiency from dietary vitamin K restriction in humans. Am J Clin Nutr 1988; 47:475-480.
21. Bolton-Smith C, Price RJ, Fenton ST et al. Compilation of a provisional UK database for the phylloquinone (vitamin K1) content of foods. Br J Nutr 2000;83:389-399.
22. Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974;15:424-430.
23. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974;16:348-354.
24. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74.
25. Toon S, Low LK, Gibaldi M et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 1986; 39:15-24.
26. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976;295:354-357.
27. O'Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980;302:33-35.
28. Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997;17:917-928.
29. Redman AR. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 2001;21: 235-242.
30. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 2003;33(Suppl. 2):23-30.
31. Bloch A, Ben Chetrit E, Muszkat M et al. Major bleeding caused by warfarin in a genetically susceptible patient. Pharmacotherapy 2002;22:97-101.
32. Gurwitz JH, Avorn J, Ross-Degnan D et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992;116:901-904.
33. Mungall D, White R. Aging and warfarin therapy. Ann Intern Med 1992;117:878-879.
34. O'Reilly RA, Pool JG, Aggeler PM. Hereditary resistance to coumarin anticoagulant drugs in man and rat. Ann N Y Acad Sci 1968;151: 913-931.
35. Holt RJ, Freytes CO. Familial warfarin resistance. Drug Intell Clin Pharm 1983;17:281-283.
36. Alving BM, Strickler MP, Knight RD et al. Hereditary warfarin resistance. Investigation of a rare phenomenon. Arch Intern Med 1985; 145:499-501.
37. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004;76:178-184.
38. Ageno W, Ambrosini F, Nardo B et al. Atrial fibrillation and antithrombotic treatment in Italian hospitalized patients: a prospective, observational study. J Thromb Thrombolysis 2001;12:225-230.
39. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998;97:1231-1233.
40. Gross CP, Vogel EW, Dhond AJ et al. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther 2003;25: 1750-1764.
41. Pradhan AA, Levine MA. Warfarin use in atrial fibrillation: A random sample survey of family physician beliefs and preferences. Can J Clin Pharmacol 2002;9:199-202.
42. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003;41:1445-1451.
43. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-19.
44. Hirsh J, Valentin F, Ansell J et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003;107:1692-1711.